Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clear Me: Opdualag vs Nivolumab in High Risk Melanoma with Detectable ctDNA
NCT06319196Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Nov 2026
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in melanoma, sponsored by University Health Network. Started Nov 2026; status: recruiting.
02
Drugs
relatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06319196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319196.